" class="no-js "lang="en-US"> Enosi Therapeutics Partners with Danuo Science Group to Accelerate Multiple Therapeutic Programs - Medtech Alert
Monday, June 17, 2024

Enosi Therapeutics Partners with Danuo Science Group to Accelerate Multiple Therapeutic Programs

Enosi Therapeutics, a Delaware Corporation, focused on providing industry-leading therapeutics for cancer and autoimmune diseases, has announced a partnership with Danuo Science Group, based in Hong Kong, to further develop two products currently in Enosi’s pipeline for Greater China.

Enosi’s Growth Factor Trap (EN-2000 Program) and TNFR1 Blocker (EN-1000 Program) were licensed as part of the partnership. Both programs have the potential to be used as cross-over drugs to treat cancer and autoimmune diseases. EN-2000 blocks inflammatory growth factors that drive cancer and rheumatoid arthritis while EN-1000 is a specific blocker of TNFR1, which Enosi believes may be useful in treating autoimmune disease, cognitive disorders and other disorders. Enosi’s programs are intended to help the 50% of cancer and autoimmune disease patients that do not benefit from current therapies.

Danuo will provide $5M in upfront licensing fees and certain conditional funding. With technical support from Enosi, Danuo will fund development in China and provide Enosi with data to use in its own filings in ROW. Including up-front payments, Enosi estimates the value of this collaboration to be more than $100M as the Company moves through the discovery and development phases of its treatments. Both Enosi and Danuo expect the first patient to be treated in China within the next 2-3 years.

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more